Implications of bone metastasis on response to systemic therapy in patients with advanced renal cell carcinoma: A systematic literature review.

Autor: Brown J; Division of Clinical Medicine, University of Sheffield, Sheffield, UK. Electronic address: j.e.brown@sheffield.ac.uk., Santini D; Medical Oncology A, Policlinico Umberto 1, La Sapienza University of Rome, Italy., Charnley N; Lancashire Teaching Hospitals, Cancer Services, Preston, UK., Ogareva A; Ipsen, Boulogne-Billancourt, France., Chisholm A; Oxford PharmaGenesis, Oxford, UK., Jones R; School of Cancer Sciences, University of Glasgow, Glasgow, UK.
Jazyk: angličtina
Zdroj: Cancer treatment reviews [Cancer Treat Rev] 2024 Sep; Vol. 129, pp. 102792. Date of Electronic Publication: 2024 Jun 26.
DOI: 10.1016/j.ctrv.2024.102792
Abstrakt: Introduction: Bone metastases negatively affect prognosis in patients with advanced renal cell carcinoma (aRCC). We conducted a systematic literature review to identify clinical trial publications including patients with aRCC with and without bone metastases.
Methods: The review was conducted according to Preferred Reporting Items for Systematic Reviews and Meta‑Analyses (PRISMA) guidelines and registered with PROSPERO (CRD42022355436). MEDLINE and Embase databases were searched (September 2, 2022) to identify publications reporting efficacy and safety outcomes for patients with/without bone metastasis from clinical trials of systemic RCC therapies. Risk of bias was assessed using Grading of Recommendations Assessment, Development and Evaluation (GRADE).
Results: Of 526 publications screened, 19 were eligible: seven (from five studies) reported phase 3 trials, six reported phase 2 trials, one reported phase 1b/2 trials, and five were pooled analyses. Five publications reported moderate-quality evidence, while 14 were graded as low- or very low-quality evidence, suggesting a high potential for uncertainty. Five studies reported benefits of investigational therapies versus comparators in patients with and without bone metastases; these studies included cabozantinib, nivolumab, cabozantinib plus nivolumab, and lenvatinib plus pembrolizumab treatment arms. Data were also available for nivolumab plus ipilimumab. Bone metastases were consistently associated with poor prognosis in patients with aRCC. Preliminary data support the hypothesis that therapies targeting pathways implicated in the development of bone metastases may be beneficial, and warrant further investigation. However, data to support treatment decision-making are lacking.
Conclusion: Our findings highlight the need for clinical data to assist in defining the optimal treatment for patients with aRCC and bone metastasis.
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Janet Brown: Honoraria: Novartis, Bayer, Amgen, Ipsen, MSD Oncology, Bristol Myers Squibb. Consulting or Advisory Role: Novartis, Bayer, Amgen, Ipsen, MSD Oncology, Bristol Myers Squibb. Speakers’ Bureau: Ipsen, Amgen, MSD. Research Funding: Amgen (Inst), Bayer (Inst). Travel, Accommodations, Expenses: Ipsen, MSD Oncology, Amgen, Novartis, Bayer. Daniele Santini: Honoraria: Speaker honoraria with AstraZeneca, MSD, BMS, Astellas, Janssenn, EISAI, Merck, Pfizer, Bayer, Novartis, AstraZeneca, Lilly. Consulting or Advisory Role: Advisory Board role with AstraZeneca, MSD, BMS, Astellas, Janssenn, EISAI, Merck, Pfizer, Bayer, Novartis, AstraZeneca, Lilly. Natalie Charnley: Honoraria: Lecture fees from Pfizer, Ipsen, and Janssen. Consulting or Advisory Role: Advisory boards with Pfizer, Ipsen, and Janssen. Alessia Ogareva: Employment: Employee of Ipsen. Alison Chisholm: Employee of Oxford PharmaGenesis. Robert Jones: Honoraria: Roche, AstraZeneca, Bristol Myers Squibb, Bayer, Astellas, Janssen, MSD, Pfizer, Merck Serono. Consulting or Advisory Role: Roche, AstraZeneca, Bristol Myers Squibb, Bayer, Novartis/AAA, Astellas, Janssen, MSD, Pfizer, Merck Serono. Research Funding: Received educational grants from Astellas, Bayer, Clovis and Exelixis.
(Copyright © 2024. Published by Elsevier Ltd.)
Databáze: MEDLINE
Externí odkaz: